SKPin C1

SKPin C1 (CAS No.: 432001-69-9) is a synthetic small-molecule research tool compound classified as a selective inhibitor of the F-box protein Skp2 in the Skp1–Cullin1–F-box (SCF) E3 ubiquitin ligase complex, intended for use in biomedical research related to the cell cycle and protein homeostasis (proteostasis), as well as early-stage target validation in drug discovery; it acts at the Skp2 and Cks1-dependent interaction interface, blocking recognition and ubiquitination of the cyclin-dependent kinase inhibitor p27 Kip1, thereby promoting the stabilization and accumulation of nuclear p27, limiting cell cycle-related kinase activity, and delaying cell cycle progression, with proliferation inhibition and apoptotic phenotypes potentially observed in specific cellular contexts; in vitro activity at the cellular level is typically in the low to mid-micromolar range, and in biochemical reconstitution systems is commonly at the tens of micromolar level, with existing in vitro evidence showing inhibition of p27 ubiquitination at approximately 50 micromolar, as well as research observations of increased nuclear p27 in endometrial cancer ECC-1 cells and restricted proliferation recorded in metastatic melanoma cell models; typical applications include mechanistic analysis of the Skp2–p27 axis, pathway-centered phenotypic screening, evaluation of cell cycle checkpoints, and studies of apoptosis and proliferation in human tumor cell lines of various origins, and it may also be used in preclinical research models to investigate scientific questions such as target engagement and pharmacodynamic biomarkers; the specific concentration or dose used in experiments depends on the experimental design and research objectives, and this product is for laboratory research use only by appropriately qualified professionals, not for human-related use or any non-research purpose.